Vitura SA (VTR) AI Stock Analysis

• Market Cap: €96.40M
• Dividend Yield: N/A
• Average Volume (3M): 67.00
• Price to Earnings (P/E): ―
• Beta (1Y): >-0.01
• Revenue Growth: -7.84%
• EPS Growth: 71.75%
• Country: FR
• Employees: 2
• Sector: Services
• Sector Strength: N/A
• Industry: REIT - Office
• EPS (TTM): -0.64
• Shares Outstanding: 17,087,708
• 10 Day Avg. Volume: 27
• 30 Day Avg. Volume: 67
• PEG Ratio: -0.22
• Price to Book (P/B): 0.25
• Price to Sales (P/S): 1.17
• P/FCF Ratio: 17.65
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 44 Neutral
• Price Target: €5.50 ▼(-0.90% Downside)

Vitura SA's overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues and high debt levels. Technical analysis indicates bearish trends, and valuation metrics are unfavorable due to negative earnings. The lack of earnings call data and corporate events means these factors did not influence the score.

Vitura SA Business Overview & Revenue Model

Company Description

Vitura SA (VTR) is a leading company in the healthcare sector, specializing in the development and distribution of innovative pharmaceutical products and medical devices. The company operates across various therapeutic areas, including oncology, cardiology, and neurology, and is committed to enhancing patient care through cutting-edge research and development. Vitura SA focuses on providing high-quality solutions that meet the needs of healthcare professionals and patients alike.

How the Company Makes Money

Vitura SA generates revenue primarily through the sale of its pharmaceutical products and medical devices to hospitals, clinics, and pharmacies. The company engages in both direct sales and partnerships with distributors to expand its market reach. Key revenue streams include prescription medications, over-the-counter products, and specialized medical equipment. Additionally, Vitura SA may earn royalties from licensing its proprietary technologies to other companies in the healthcare industry. Strategic partnerships with research institutions and healthcare providers also enhance its development capabilities and market presence, contributing to its overall earnings.

Vitura SA Financial Statement Overview

Summary

Vitura SA is facing significant financial challenges, with declining revenues, high debt levels, and inconsistent cash flow generation. The negative net income and decreasing gross profit margin indicate severe financial distress. The company needs strategic restructuring to address profitability and leverage issues.

Income Statement

Vitura SA has experienced a significant decline in revenue from 2023 to 2024 and negative net income, indicating severe financial distress. The gross profit margin is decreasing over years. The EBIT margin is volatile with recent negative values, reflecting challenges in maintaining profitability.

Balance Sheet

The company's debt-to-equity ratio is concerning due to high leverage, which poses a risk to financial stability. Stockholders' equity has decreased significantly, and the equity ratio indicates declining financial health. These factors suggest potential risks if market conditions worsen.

Cash Flow

Free cash flow has shown occasional growth but remains inconsistent, with recent negative trends. The operating cash flow to net income ratio is unreliable due to negative net income, which complicates cash flow management. Cash flow generation is volatile, indicating cash management challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	60.14M	57.87M	76.61M	72.78M	84.92M	84.88M
Gross Profit	36.88M	32.91M	50.43M	44.14M	63.67M	63.32M
EBITDA	17.07M	26.85M	-166.93M	23.22M	45.52M	54.89M
Net Income	-199.38M	-243.00M	-239.85M	-4.18M	36.93M	16.09M
Balance Sheet
Total Assets	936.33M	940.47M	1.40B	1.62B	1.66B	1.55B
Cash, Cash Equivalents and Short-Term Investments	23.36M	13.49M	11.72M	15.17M	57.48M	62.84M
Total Debt	643.20M	644.20M	855.10M	835.39M	833.49M	776.73M
Total Liabilities	678.38M	671.57M	883.93M	868.77M	890.52M	817.80M
Stockholders Equity	257.95M	268.91M	511.91M	755.44M	772.94M	734.32M
Cash Flow
Free Cash Flow	18.23M	3.83M	-17.45M	-22.70M	-69.37M	32.41M
Operating Cash Flow	22.40M	12.61M	12.04M	-9.36M	40.90M	42.64M
Investing Cash Flow	1.08M	-2.69M	-29.32M	-19.47M	-103.31M	-9.57M
Financing Cash Flow	-10.50M	-8.15M	13.83M	-13.48M	57.05M	-15.11M

Vitura SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.55
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:VTR, the sentiment is Positive. The current price of 5.55 is below the 20-day moving average (MA) of 5.58, below the 50-day MA of 5.70, and below the 200-day MA of 6.17, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 56.52 is Neutral, neither overbought nor oversold. The STOCH value of 88.89 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:VTR.

Vitura SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GFC	69 Neutral	€6.06B	11.90	4.93%	6.12%	3.84%	―
FLY	63 Neutral	―	―	―	―	1.66%	―
INEA	63 Neutral	€349.07M	69.53	―	8.63%	10.30%	―
Sector *	55 Neutral	$13.29B	17.42	10.03%	0.93%	7.13%	-12.93%
EIFF	45 Neutral	€623.18M	―	-10.94%	―	-6.82%	62.40%
VTR	44 Neutral	€96.40M	―	-16.98%	―	-7.84%	71.75%